CLEC12A and acute lymphoblastic leukemia: found that 27/28 (96.4%) of B-ALL cases carrying DUX4-r fusions were CD371-positive at diagnosis, compared with 7/387 (1.8%) of cases of other subtypes, indicating very high sensitivity and specificity for CD371 detection as a marker for DUX4-r B-ALL.